Zimmer Biomet (NYSE:ZBH) Stock Crosses Below 50 Day Moving Average – Time to Sell?

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $94.86 and traded as low as $94.38. Zimmer Biomet shares last traded at $94.54, with a volume of 3,605,958 shares traded.

Analyst Ratings Changes

ZBH has been the subject of several research reports. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a research report on Monday, September 28th. Truist Financial boosted their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Stifel Nicolaus increased their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Finally, Citigroup restated a “neutral” rating on shares of Zimmer Biomet in a report on Monday, October 5th. Seven research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $104.47.

Zimmer Biomet Price Performance

The company has a market cap of $18.03 billion, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 2.27 and a beta of 0.49. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average price of $94.86 and a two-hundred day moving average price of $91.70.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. Zimmer Biomet’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were paid a $0.24 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Insider Transactions at Zimmer Biomet

In other news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. OMERS ADMINISTRATION Corp acquired a new stake in Zimmer Biomet in the second quarter worth about $922,000. Hsbc Holdings PLC acquired a new position in Zimmer Biomet during the 2nd quarter valued at about $35,417,000. Legal & General Group Plc acquired a new position in Zimmer Biomet during the 2nd quarter valued at about $126,167,000. Rakuten Investment Management Inc. acquired a new position in Zimmer Biomet during the 2nd quarter valued at about $2,945,000. Finally, Nykredit A S bought a new position in shares of Zimmer Biomet in the 2nd quarter valued at about $3,419,000. Institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.